BioSpace News Archive

Scinai Immunotherapeutics Ltd. announced receipt of a letter from the Nasdaq Stock Market dated November 1, 2023, regarding non-compliance with the requirement to maintain a minimum bid price of $1.00 per share.

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”) today announced promising updated preliminary translational data from the ongoing Phase 1 (AMPLIFY-201) study of its lead cancer vaccine candidate, ELI-002, in patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers, and new preclinical data on vaccine candidates, ELI-007 and ELI-008.

Aeglea BioTherapeutics, Inc. announced that Aeglea’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 729,600 shares of common stock of Aeglea to six non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended.

Compugen Ltd. announced that on November 3, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5550.

Aligos Therapeutics, Inc. announced that announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Professor of Medicine at the Johns Hopkins University School of Medicine, to review the Late Breaking results and next steps for ALG-000184, its Phase 1 CAM-E drug candidate for chronic Hepatitis B, and the unmet need and current treatment landscape for patients with CHB on November 16, 2023 at 1:30 PM ET.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI®.

Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of aprocitentan on blood pressure lowering and proteinuria in patients with chronic kidney disease and resistant hypertension” by George Bakris, MD, at the American Society of Nephrology (ASN) Kidney Week 2023.

BioUtah today announced the winners of its 2023 Life Sciences Awards. Five awards will be presented during the 2023 Mayer Brown Utah Life Sciences Summit Nov. 9 at the Salt Palace, in Salt Lake City.

Starton Therapeutics Inc. announced that it notified Healthwell Acquisition Corp. I that the Company had elected to terminate the business combination agreement among Starton, Healthwell and the other parties thereto dated as of April 27, 2023, as amended, effective immediately.

BioInvent International AB (“BioInvent”) (Nasdaq Stockholm:BINV) today presents the latest data from a Phase 1/2a trial of its first-in-class anti-tumor necrosis factor receptor 2 (TNFR2) antibody BI-1808 as a single agent, at the Society of Immunotherapy for Cancer (SITC) 38th Annual Meeting in San Diego,